CG
EPRS

Cutler Group’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Cutler Group’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-850
Closed -$2K – 7977
2015
Q4 		$2K Buy
+850
New +$3.83K ﹤0.01% 5804

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cutler Group's EPRS Position: Q1 2016 in Review

Cutler Group sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q1 2016, closing a stake of 850 shares — an estimated $2K sold.

Cutler Group first reported a position in EPRS in Q4 2015 and held it in 1 quarter. The position peaked at $2K in Q4 2015. 37 funds tracked by Wall St. Rank hold EPRS as of Q1 2016.

  • Cutler Group reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q1 2016 after selling out during the quarter.
  • Cutler Group sold 850 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q1 2016, an estimated $2K.
  • Cutler Group first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2015 and held it in 1 quarter.
  • Cutler Group's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $2K in Q4 2015.
  • 37 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q1 2016.

Based on Cutler Group's 13F filing for Q1 2016, filed 8 Jun 2016.